Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

517 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Refining sorafenib therapy: lessons from clinical practice.
Bolondi L, Craxi A, Trevisani F, Daniele B, Di Costanzo GG, Fagiuoli S, Cammà C, Bruzzi P, Danesi R, Spandonaro F, Boni C, Santoro A, Colombo M. Bolondi L, et al. Among authors: danesi r. Future Oncol. 2015;11(3):449-65. doi: 10.2217/fon.14.261. Epub 2014 Oct 31. Future Oncol. 2015. PMID: 25360997 Free article. Review.
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma.
Brandi G, Biasco G, Mirarchi MG, Golfieri R, Di Paolo A, Borghi A, Fanello S, Derenzini E, Agostini V, Giampalma E, Cappelli A, Pini P, Costantini S, Danesi R, Bolondi L, Piscaglia F. Brandi G, et al. Among authors: danesi r. Dig Liver Dis. 2011 Dec;43(12):1015-21. doi: 10.1016/j.dld.2011.08.005. Epub 2011 Sep 13. Dig Liver Dis. 2011. PMID: 21917536 Clinical Trial.
Individualized dosing with axitinib: rationale and practical guidance.
Schmidinger M, Danesi R, Jones R, McDermott R, Pyle L, Rini B, Négrier S. Schmidinger M, et al. Among authors: danesi r. Future Oncol. 2018 Apr;14(9):861-875. doi: 10.2217/fon-2017-0455. Epub 2017 Dec 21. Future Oncol. 2018. PMID: 29264944 Free article. Review.
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.
Giovannetti E, Zucali PA, Peters GJ, Cortesi F, D'Incecco A, Smit EF, Falcone A, Burgers JA, Santoro A, Danesi R, Giaccone G, Tibaldi C. Giovannetti E, et al. Among authors: danesi r. Mol Cancer Ther. 2010 Mar;9(3):581-93. doi: 10.1158/1535-7163.MCT-09-0665. Epub 2010 Feb 16. Mol Cancer Ther. 2010. PMID: 20159991 Free article.
Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.
Toffalorio F, Spitaleri G, Catania C, Dal Zotto L, Noberasco C, Delmonte A, Santarpia M, Vecchio F, Brunelli V, Rampinelli C, Barberis M, Fumagalli C, Zucchetti M, Zangarini M, Diena T, Danesi R, de Braud F, De Pas T. Toffalorio F, et al. Among authors: danesi r. Oncologist. 2014 Apr;19(4):344-5. doi: 10.1634/theoncologist.2013-0335. Epub 2014 Mar 27. Oncologist. 2014. PMID: 24674875 Free PMC article. Clinical Trial.
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life.
Matrone A, Valerio L, Pieruzzi L, Giani C, Cappagli V, Lorusso L, Agate L, Puleo L, Viola D, Bottici V, Del Re M, Molinaro E, Danesi R, Elisei R. Matrone A, et al. Among authors: danesi r. Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):319-334. doi: 10.1016/j.beem.2017.06.001. Epub 2017 Jun 15. Best Pract Res Clin Endocrinol Metab. 2017. PMID: 28911728 Review.
517 results